2025-05-28-Jefferies-龙沙集团（LONN）_勘误_新业务细分的初步分析_16页_1mb

Lonza Group AG Equity Research Summary

Company Overview

Lonza Group AG is a European life sciences company focused on manufacturing active pharmaceutical ingredients for biologics, small molecules, and cell and gene therapies. As part of a recent organizational reorganization, the company has realigned into new segments: Integrated Biologics, Advanced Synthesis, Specialized Modalities, and Capsules. The Jefferies equity research report updates its SOTP (Sum-of-the-Parts) model to reflect these changes, maintaining unchanged forecasts and price target based on market dynamics and growth potential in areas like biologics and contract development and manufacturing organization (CDMO) services.

Key Findings

• Rating and Price Target: BUY with a CHF715 price target, implying a 26% upside from the prior trading day's closing price of CHF568. The PT is supported by projected sales growth and smooth operational performance, while down-side scenarios consider risks like reduced demand or margin pressures.
• Market Position: Lonza benefits from strong visibility in pharmaceutical manufacturing, particularly in high-margin biologics and CDMO collaborations, underpinning confidence in mid-teen EPS compound annual growth rates (CAGRs).

Segmentation and Financial Projections

• New Segments:
  • Integrated Biologics (excluding mRNA and microbial lines) shows robust growth with a core EBITDA margin expansion as facilities like Vacaville ramp up.
  • Advanced Synthesis incorporates bioconjugates and small molecules, valued at around 35.5% margin, with steady revenue growth.
  • Specialized Modalities includes cell and gene therapy, mRNA, and microbial products under a lower-margin, higher-growth profile.
  • Capsules maintain stable operations with no margin adjustments.
• Growth Outlook: Revenue is projected to increase from CHF6,574 million in 2024 to CHF9,224 million by 2027, driven by sales growth across segments. EBITDA is expected to reach CHF2,833 million by 2027, with improving margins.
• Multiples and Valuation Drivers: The target multiple stands at 42.5x 2025E P/E and 24.2x EV/EBITDA, shifting with segment reallocations. A DCF analysis using sum-of-the-parts model supports the PT, considering value from existing contracts and growth projects.

Investment Thesis and Risks

• Up-side: Greater operational efficiencies, demand growth in biologics and CDMO services, and successful contract wins could drive stock price higher, with upside scenarios reaching CHF903 (+59%).
• Down-side: Lower revenue growth or margin erosion may lead to a PT cut to CHF472 (-17%). Key risks include failing to secure future contracts, regulatory inspection failures, pricing pressure from competition, and integration challenges with new technologies.
• Economic and Market Factors: Lonza leverages sustainability targets (e.g., renewable energy use by 2025) and ESG initiatives, which are increasingly relevant in its sector. Peer comparisons show Lonza at 28.7x EV/EBITDA, competitive in CDMO markets.

Conclusion

Jefferies maintains a BUY recommendation, grounded in Lonza's strong position in high-growth pharmaceutical manufacturing. Investors should monitor upcoming 1H results (July 23) and key catalysts like new CDMO collaborations for revised forecasts.